Investors

XOMA Congratulates Sesen Bio on Successful Pre-BLA Meeting with FDA for Vicinium®

Jun 18, 2019

XOMA congratulates Sesen Bio on a successful pre-BLA meeting with the FDA regarding Vicinium for the treatment of patients with high-risk, Bacillus Calmette-Guérin unresponsive, non-muscle invasive bladder cancer. Vicinium is one of the products in which XOMA has a royalty interest.

http://ir.sesenbio.com/news-releases/news-release-details/sesen-bio-announces-successful-pre-bla-meeting-fda-viciniumr